MX344601B - Tratamiento de enfermedades asociadas con el uso de antibioticos. - Google Patents
Tratamiento de enfermedades asociadas con el uso de antibioticos.Info
- Publication number
- MX344601B MX344601B MX2014003990A MX2014003990A MX344601B MX 344601 B MX344601 B MX 344601B MX 2014003990 A MX2014003990 A MX 2014003990A MX 2014003990 A MX2014003990 A MX 2014003990A MX 344601 B MX344601 B MX 344601B
- Authority
- MX
- Mexico
- Prior art keywords
- antibiotics
- treatment
- diseases associated
- colitis
- resistant
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Virology (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Saccharide Compounds (AREA)
Abstract
Esta invención se refiere al tratamiento o prevención de enfermedades asociadas con el uso de antibióticos o quimioterapias para el cáncer o terapias antivirales, tales como colitis, colitis pseudomembranosa, diarrea asociada a antibióticos e infecciones debidas a especies de C. difficile, c. perfringens, Staphylococcus incluyendo Staphylococcus aureus resistente a la meticilina (MRSA) o Enterococcus, incluyendo los enterococos resistentes a la vancomicina (VRE) con el Compuesto I.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US57069704P | 2004-05-14 | 2004-05-14 | |
PCT/US2005/016750 WO2005112990A2 (en) | 2004-05-14 | 2005-05-13 | Treatment of diseases associated with the use of antibiotics |
Publications (1)
Publication Number | Publication Date |
---|---|
MX344601B true MX344601B (es) | 2016-12-20 |
Family
ID=35428857
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MXPA06013245A MXPA06013245A (es) | 2004-05-14 | 2005-05-13 | Tratamiento de enfermedades asociadas con el uso de antibioticos. |
MX2014003990A MX344601B (es) | 2004-05-14 | 2005-05-13 | Tratamiento de enfermedades asociadas con el uso de antibioticos. |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MXPA06013245A MXPA06013245A (es) | 2004-05-14 | 2005-05-13 | Tratamiento de enfermedades asociadas con el uso de antibioticos. |
Country Status (17)
Country | Link |
---|---|
US (2) | US20070173462A1 (es) |
EP (4) | EP2305245B1 (es) |
JP (2) | JP5734545B2 (es) |
AT (1) | ATE516024T1 (es) |
BR (1) | BRPI0511119A (es) |
CA (2) | CA2776682A1 (es) |
CY (2) | CY1117501T1 (es) |
DK (3) | DK2305244T3 (es) |
ES (4) | ES2565609T3 (es) |
HU (3) | HUE031581T2 (es) |
LT (1) | LT2305245T (es) |
MX (2) | MXPA06013245A (es) |
PL (3) | PL2305244T3 (es) |
PT (2) | PT2305244T (es) |
SI (2) | SI2070530T1 (es) |
TR (1) | TR201902533T4 (es) |
WO (1) | WO2005112990A2 (es) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7906489B2 (en) * | 2004-05-14 | 2011-03-15 | Optimer Pharmaceuticals, Inc. | 18-membered macrocycles and analogs thereof |
US7378508B2 (en) * | 2007-01-22 | 2008-05-27 | Optimer Pharmaceuticals, Inc. | Polymorphic crystalline forms of tiacumicin B |
MX340742B (es) * | 2005-01-31 | 2016-07-21 | Merck Sharp & Dohme | Compuestos macrociclicos de 18 miembros y analogos de los mismos. |
WO2007048059A2 (en) * | 2005-10-21 | 2007-04-26 | Optimer Pharmaceuticals, Inc. | Method of treating clostridium difficile-associated diarrhea |
TWI523654B (zh) * | 2007-11-27 | 2016-03-01 | 默沙東藥廠 | 抗生素巨環化合物以及其製造及使用之方法 |
WO2009117310A2 (en) * | 2008-03-17 | 2009-09-24 | Cedars-Sinai Medical Center | Methods for treatment and prevention of mrsa/mssa |
WO2011044208A1 (en) * | 2009-10-06 | 2011-04-14 | Scott Dorfner | Antibiotic formulations providing reduced gastrointentestinal side effects |
WO2011061667A1 (en) * | 2009-11-17 | 2011-05-26 | Piramal Life Sciences Limited | Use of macrocyclic lactone derivatives for the treatment of inflammatory disorders |
AU2010339573B2 (en) * | 2009-12-31 | 2014-08-28 | Ira Milton Trachtman | Compositions and method for treatment and prophylaxis of inflammatory bowel disease |
CA2799386A1 (en) * | 2010-05-18 | 2011-11-24 | Optimer Pharmaceuticals, Inc. | Treatment of clostridium difficile infection in patients undergoing antibiotic therapy |
JO3464B1 (ar) | 2013-01-15 | 2020-07-05 | Astellas Pharma Europe Ltd | التركيبات الخاصة بمركبات التياكوميسين |
CA2948400A1 (en) * | 2014-05-09 | 2015-11-12 | Astellas Pharma Europe Ltd | Treatment regimen tiacumicin compound |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3279995A (en) | 1963-05-31 | 1966-10-18 | Allen F Reid | Shaped pellets |
GB1458512A (en) * | 1973-11-22 | 1976-12-15 | Lepetit Spa | Antibiotic substance |
US4111202A (en) | 1976-11-22 | 1978-09-05 | Alza Corporation | Osmotic system for the controlled and delivery of agent over time |
US4918174A (en) * | 1986-09-26 | 1990-04-17 | Abbott Laboratories | Tiacumicin compounds |
US4786503A (en) | 1987-04-06 | 1988-11-22 | Alza Corporation | Dosage form comprising parallel lamine |
US5443841A (en) | 1992-06-15 | 1995-08-22 | Emisphere Technologies, Inc. | Proteinoid microspheres and methods for preparation and use thereof |
US6235313B1 (en) | 1992-04-24 | 2001-05-22 | Brown University Research Foundation | Bioadhesive microspheres and their use as drug delivery and imaging systems |
US5792451A (en) | 1994-03-02 | 1998-08-11 | Emisphere Technologies, Inc. | Oral drug delivery compositions and methods |
US5672659A (en) | 1993-01-06 | 1997-09-30 | Kinerton Limited | Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides |
US5583115A (en) * | 1995-05-09 | 1996-12-10 | Abbott Laboratories | Dialkyltiacumicin compounds |
US6143211A (en) | 1995-07-21 | 2000-11-07 | Brown University Foundation | Process for preparing microparticles through phase inversion phenomena |
US5767096A (en) * | 1996-07-12 | 1998-06-16 | Abbott Laboratories | Bromotiacumicin compounds |
IN186245B (es) | 1997-09-19 | 2001-07-14 | Ranbaxy Lab Ltd | |
ES2327830T3 (es) * | 2002-03-29 | 2009-11-04 | Schering Corporation | Anticuerpos monoclonales humanos anti-interleuquina-5 y metodos y composiciones que los contienen. |
AU2003251902B2 (en) | 2002-07-29 | 2008-03-06 | Merck Sharp & Dohme Llc | Tiacumicin production |
US20070105791A1 (en) * | 2002-07-29 | 2007-05-10 | Optimer Pharmaceuticals, Inc. | Method of treating clostridium difficile-associated diarrhea |
US7906489B2 (en) * | 2004-05-14 | 2011-03-15 | Optimer Pharmaceuticals, Inc. | 18-membered macrocycles and analogs thereof |
US7378508B2 (en) * | 2007-01-22 | 2008-05-27 | Optimer Pharmaceuticals, Inc. | Polymorphic crystalline forms of tiacumicin B |
ZA200905337B (en) * | 2007-01-22 | 2010-10-27 | Optimer Pharmaceuticals Inc | Macrocyclic polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof |
TWI523654B (zh) * | 2007-11-27 | 2016-03-01 | 默沙東藥廠 | 抗生素巨環化合物以及其製造及使用之方法 |
-
2005
- 2005-05-13 BR BRPI0511119-6A patent/BRPI0511119A/pt not_active IP Right Cessation
- 2005-05-13 ES ES09156339.5T patent/ES2565609T3/es active Active
- 2005-05-13 DK DK10075449.8T patent/DK2305244T3/en active
- 2005-05-13 EP EP10075450.6A patent/EP2305245B1/en active Active
- 2005-05-13 SI SI200532054A patent/SI2070530T1/sl unknown
- 2005-05-13 ES ES10075450T patent/ES2713954T3/es active Active
- 2005-05-13 PT PT100754498T patent/PT2305244T/pt unknown
- 2005-05-13 TR TR2019/02533T patent/TR201902533T4/tr unknown
- 2005-05-13 LT LTEP10075450.6T patent/LT2305245T/lt unknown
- 2005-05-13 MX MXPA06013245A patent/MXPA06013245A/es active IP Right Grant
- 2005-05-13 JP JP2007513392A patent/JP5734545B2/ja active Active
- 2005-05-13 WO PCT/US2005/016750 patent/WO2005112990A2/en active Application Filing
- 2005-05-13 US US11/596,340 patent/US20070173462A1/en not_active Abandoned
- 2005-05-13 DK DK09156339.5T patent/DK2070530T3/da active
- 2005-05-13 PL PL10075449T patent/PL2305244T3/pl unknown
- 2005-05-13 EP EP10075449.8A patent/EP2305244B1/en active Active
- 2005-05-13 CA CA2776682A patent/CA2776682A1/en not_active Withdrawn
- 2005-05-13 PL PL10075450T patent/PL2305245T3/pl unknown
- 2005-05-13 EP EP05748007A patent/EP1765312B1/en active Active
- 2005-05-13 PT PT10075450T patent/PT2305245T/pt unknown
- 2005-05-13 HU HUE10075449A patent/HUE031581T2/en unknown
- 2005-05-13 AT AT05748007T patent/ATE516024T1/de not_active IP Right Cessation
- 2005-05-13 DK DK10075450.6T patent/DK2305245T3/en active
- 2005-05-13 HU HUE10075450A patent/HUE043945T2/hu unknown
- 2005-05-13 PL PL09156339T patent/PL2070530T3/pl unknown
- 2005-05-13 ES ES10075449.8T patent/ES2608046T3/es active Active
- 2005-05-13 HU HUE09156339A patent/HUE027757T2/en unknown
- 2005-05-13 MX MX2014003990A patent/MX344601B/es unknown
- 2005-05-13 EP EP09156339.5A patent/EP2070530B1/en active Active
- 2005-05-13 CA CA2566687A patent/CA2566687C/en active Active
- 2005-05-13 ES ES05748007T patent/ES2395404T3/es active Active
- 2005-05-13 SI SI200532245T patent/SI2305245T1/sl unknown
-
2012
- 2012-04-26 US US13/457,216 patent/US20130274175A1/en not_active Abandoned
- 2012-06-19 JP JP2012138170A patent/JP6101010B2/ja active Active
-
2016
- 2016-05-13 CY CY20161100404T patent/CY1117501T1/el unknown
-
2019
- 2019-02-28 CY CY20191100248T patent/CY1121284T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MXPA06013245A (es) | Tratamiento de enfermedades asociadas con el uso de antibioticos. | |
MX2009007730A (es) | Polimorfos macrocilicos, composiciones que comprenden tales polimorfos, y metodos para su uso y fabricacion. | |
EP1710248A4 (en) | NEW AMINOGLYCOSIDE ANTIBIOTICS WITH EFFECT ON METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS (MRSA) | |
WO2004017925A3 (en) | Methods and reagents for preventing bacteremias | |
EP2322930A3 (en) | Sequences for detection and identification of methicillin-resistant Staphylococcus Aureus (MRSA) of MREJ type xiv | |
SG153833A1 (en) | Methods of treatment of endobronchial infections | |
GB2480772A (en) | Compositions and methods for the treatment or prevention of staphylococcus aureus infections and for the eradication or reduction of staphylococcus aureus | |
CO2019011264A2 (es) | Nanosistemas que comprenden plata y antibióticos y su uso para el tratamiento de infecciones bacterianas | |
MX2022000233A (es) | Inhibidores de deteccion de quórum y/o metabolitos posbióticos y métodos relacionados. | |
MX2017003938A (es) | Antibioticos no beta-lactamicos. | |
MX2018006190A (es) | Antibioticos de amplio espectro macrociclico. | |
NZ788133A (en) | Cd73 inhibitors | |
NZ545472A (en) | 7-(4-substituted-3-cyclopropylaminomethyl-1-pyrrolidinyl)quinolonecarboxylic acid derivative | |
MX2021005740A (es) | Novedoso compuesto como inhibidor de proteina quinasa, y composicion farmaceutica que comprende el mismo. | |
MX2018011046A (es) | Composiciones y metodos para tratar canceres. | |
IN2014CN02908A (es) | ||
PH12021551058A1 (en) | Antibiotic compounds, methods of manufacturing the same, pharmaceutical compositions containing the same and uses thereof | |
WO2009001192A3 (en) | Novel compounds and their use | |
WO2017040762A3 (en) | Methods for identifying novel antibiotics and related compositions | |
WO2010131865A3 (ko) | 항생제 내성 균주에 대한 항균용 조성물 | |
WO2019070709A8 (en) | Compounds for treating or preventing flavivirus infections | |
IN2012DN00740A (es) | ||
EP4026271A4 (en) | HUMAN-READABLE AND MACHINE-READABLE CRYPTOGRAPHIC KEYS, OBTAINED FROM DICE | |
AU2018445889A8 (en) | Antimicrobial peptides and methods of using the same | |
WO2003068791A3 (en) | Macrolides with activity against methicillin-resistant staphylococcus aureus |